Update re. proposed cancellation of shares

Summary by AI ^BETAClose X

Tissue Regenix Group plc has provided an update regarding the proposed cancellation of its shares, stating that it expects to remain solvent if resolutions pass at the General Meeting on December 22, 2025, and the initial £7.5 million of a Secured Convertible Loan Note is drawn down. However, due to ongoing financial challenges and uncertainty, the Board cannot definitively clarify the company's financial position before the proposed cancellation date of January 7, 2026, meaning trading in Ordinary Shares will remain suspended. A matched bargain facility will be available for shareholders for at least a year from January 7, 2026.

Disclaimer*

Tissue Regenix Group PLC

08 December 2025

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')

Update re. proposed cancellation of shares

Tissue Regenix (AIM: TRX), the regenerative medical devices company, provides a further update on the proposed cancellation of its shares.

Further to the announcement of 4 December 2025, the Company expects to remain solvent assuming that the Resolutions are passed at the General Meeting on 22 December 2025 and the initial £7.5m of the Secured Convertible Loan Note is drawn down shortly thereafter.

However, in light of the ongoing financial challenges facing the Company and continued uncertainty over its current trading position, the Board does not believe it will be able to clarify Tissue Renegix's financial position with any degree of certainty ahead of the proposed Cancellation date. As a result, trading in the Ordinary Shares will remain suspended ahead of Cancellation on 7 January 2026.

There will be a matched bargain facility in place from 7 January 2026 for a period of at least a year which will allow Shareholders to trade on a matched bargain basis.

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement made by the Company on 4 December 2025.

For more information, please contact:

Tissue Regenix Group plc
Jay LeCoque, Executive Chairman	via Walbrook PR
Cavendish Capital Markets (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Edward Whiley Nigel Birks - Life Science Specialist Sales Harriet Ward - ECM	Tel: +44 (0) 20 7466 5000
Walbrook PR (Financial PR and IR)	Tel: +44 (0)20 7933 8780
Alice Woodings / Lianne Applegarth	Tissue Regenix@walbrookpr.com

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END